Category Archives: Other

Novo Advances Amycretin to Ph3; Medtronic Diabetes Reclaims MiniMed Name; Vertex Layoffs After Failed T1DM Program 

Three cardiometabolic-related news items have been observed: Novo Nordisk advances amycretin into Ph3 development (view press release); Medtronic named its diabetes spinoff company “MiniMed” (view press release); and Vertex lays off employees due to its failed T1DM program (view article). Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Register
Already a member? Log in here

Tandem to Integrate with Abbott’s Glucose-Ketone Sensor; Insulet iOS App Integrates with Dexcom; Ypsomed and CamDiab Expand mylife Loop iOS; BI/Echosens Expand Partnership in MASH; Altimmune Initiates New Ph2 Study in ALD 

A series of cardiometabolic-related news items has been observed from Tandem Diabetes Care/Abbott, Insulet/Dexcom, Ypsomed/CamDiab, Boehringer Ingelheim/Echosens, and Altimmune. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Omada Releases IPO Pricing; EMA Concludes New Semaglutide Side Effect 

Two cardiometabolic-related news items have been observed: Omada announced its IPO price offering (view press release); and EMA concluded that non-arteritic anterior ischemic optic neuropathy is only a “very rare” side effect associated with semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Ascletis Initiates Ph2 Obesity Study; Bayer Ph2 Finerenone + Empagliflozin CKD Results 

Two cardiometabolic news items have been observed: Ascletis Pharma initiated a Ph2 study of ASC30 in obesity (view CT.gov record); and Bayer announced Ph2 CONFIDENCE results of finerenone and empagliflozin in patients with CKD and T2DM (view press release; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Welldoc Supports Launch of New Lilly Health App; NodThera Initiates Ph2 Study of NT-0796; Virta Claims Cost Savings for Obesity Programs 

Three cardiometabolic-related news items have been observed: Welldoc announced it will power Lilly’s new app for obesity  (view press release); NodThera initiated its Ph2 RESOLVE-1 study for NT-0796 in obesity (view press release); and Virta Health announced cost savings for health plans and employers utilizing its cardiometabolic programs (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Lilly Enters Licensing Agreement for Long-Acting Therapies in CVRM; Hims & Hers Reduces Workforce; AstraZeneca Initiates Ph3 Oral PCSK9i Program 

Three cardiometabolic-related news items have been observed: Lilly entered into a licensing agreement with Camurus for long-acting drug delivery technology (view press release); Hims & Hers plans to cut 4% of its workforce (view article); and AstraZeneca initiated its Ph3 AZURE program for AZD0780 (oral PCSK9i) in patients with HeFH (AZURE-HeFH; view CT.gov record), elevated LDL (AZURE-LDL; view CT.gov record), and a CVOT (AZURE-Outcomes; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Regeneron Enters In-Licensing Agreement for Dual Agonist in Obesity and Announces Interim Ph2 Obesity Data; Nxera Achieves Milestone in Lilly Collaboration; TIXiMed Completes Ph1 Study for TIX100; Arrowhead Doses First Patients in Ph1/2a Obesity Study

A series of cardiometabolic-related news items has been observed from Regeneron Pharmaceuticals/Hansoh Pharma, Nxera Pharma, TIXiMed, and Arrowhead Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Obesity Spotlight: If Pfizer Can’t Beat ‘Em, Should It Join Them?

In the fifth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of Pfizer’s current position in the obesity market. The analysis includes insights into Pfizer’s recent discontinuation of danuglipron (oral GLP-1RA; previous FENIX insight) and potential next steps for the company, including how Pfizer’s history with CVRM alliances may influence its obesity strategy.

This content is for Read Less members only.
Register
Already a member? Log in here